One Equity Partners (OEP), a middle market private equity firm, has completed a strategic investment in InfuCare Rx, a national provider of specialty infusion therapies and comprehensive clinical therapy management services to patients with complex conditions.
InfuCare Rx, headquartered in Fairfield, New Jersey, offers specialty infusion services with a focus on immunoglobulin therapy, chronic inflammatory therapy, acute and anti-infective therapy, bleeding disorders, and parenteral nutrition to help patients manage chronic conditions. The Company has locations in New Jersey, Pennsylvania, Maryland, Louisiana, California and Texas, and services over 4,000 patients across 43 states using its InfuCare Rx digital care management platform.
Infusion therapy is a USD100 billion industry providing care in traditional settings such as hospitals, physician offices, skilled nursing facilities and alternate-site settings such as ambulatory sites and the home. The home/ambulatory settings segment is expected to grow five per cent to seven percent annually from USD14 billion in 2020 to USD18 billion in 2026.
